Immatics NV (IMTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN NL0015285941
Immatics NV financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 65.25 m USD |
| Gross profit | 65.25 m USD |
| Operating income | -205.93 m USD |
| EBIT | -247.02 m USD |
| Net income | -222.26 m USD |
| Diluted EPS – continuing operations | -2.12 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Immatics NV
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
More stocks
- China Yuchai International Ltd (CYD)
- AZUL ON N2 (AZUL3.SA)
- Aktis Oncology, Inc. Common stock (AKTS)
- Huachangda Intelligent Equipment Group Co Ltd (300278.SZ)
- Xianheng International Science & Technology Co Ltd (605056.SS)
- Savencia SA (SAVE.PA)
- Platzer Fastigheter Holding AB (publ) (PLAZ B.ST)
- Sri Trang Gloves (Thailand) Public Company Limited (STGT.BK)
- FINANCIAL INSTITUTIONS INC (FISI)
- Yijiahe Technology Co Ltd (603666.SS)
- Hubei Chaozhuo Aviation Technology Co. Ltd. A (688237.SS)
- Jasuindo Tiga Perkasa Tbk (JTPE.JK)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.